Purine Compounds Targeting Aurora A and PKC Alpha for Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are ineffective in targeting cancer stem cells and inhibiting metastasis, leading to resistance against chemotherapy and radiation therapies, and a lack of effective options for advanced metastatic cancers.
Innovation Solution
Development of novel compounds and pharmaceutical compositions that target key signaling pathways in cancer stem cells, specifically inhibiting Aurora A and protein kinase C α, to reduce cancer cell proliferation and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current chemotherapeutic and radiation therapies are used to treat cancer, then some cancer cells are killed, but cancer stem cells are not targeted and resistance develops leading to treatment failure
Solution Approach 1:
The patent employs dual-target inhibition by simultaneously blocking Aurora A kinase and Protein Kinase C alpha with a single compound. This parameter change approach targets multiple signaling pathways concurrently, preventing cancer stem cells from activating alternative survival mechanisms and overcoming the adaptability that leads to treatment resistance.
Solution Approach 2:
The compound of formula (I) serves multiple functions by inhibiting both Aurora A and Protein Kinase C alpha kinases. This multi-functionality allows a single agent to address both proliferative signaling and stem cell maintenance pathways, making the treatment effective against diverse cancer cell populations including resistant stem cells.
2Ease of operation
If conventional single-agent therapies are used, then treatment simplicity is maintained, but cancer stem cells build resistance leading to poor prognosis in metastatic cancer
Solution Approach 1:
The single compound of formula (I) exhibits dual kinase inhibition activity against Aurora A and Protein Kinase C alpha, providing combination therapy effects in a monotherapy format. This maintains ease of administration while achieving reliable outcomes by simultaneously disrupting multiple survival pathways in cancer stem cells.
Solution Approach 2:
The patent merges the functions of two separate kinase inhibitors (Aurora A inhibitor and Protein Kinase C alpha inhibitor) into a single molecular entity. This consolidation maintains treatment simplicity while achieving the synergistic effects of combination therapy, thereby improving prognosis in metastatic cancer without complicating the treatment regimen.
3Productivity
If existing anti-cancer agents are used to inhibit cell proliferation, then some tumor growth is controlled, but metastasis is not effectively inhibited due to untargeted signaling pathways
Solution Approach 1:
The compound induces parameter changes in cancer cell behavior by simultaneously inhibiting Aurora A (involved in cell division) and Protein Kinase C alpha (involved in metastasis signaling). This dual parameter control prevents both uncontrolled proliferation and metastatic spread, addressing both tumor growth and dissemination simultaneously.
Data Source
AI summary
The present disclosure relates to novel compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof; wherein R1, R2, Ra, Rb and Rc are as defined herein, pharmaceutical compositions containing same and methods for the treatment of cancer using same.